Mice Model Market Size, Share & Forecast (2025-2035)

Key Market Highlights

Mice Model Market Size Was Valued at USD 1.42 Billion in 2024, and is Projected to Reach USD 2.59 Billion by 2035, Growing at a CAGR of 5.6% from 2025-2035.

• Market Size in 2024: USD 1.42 Billion
• Projected Market Size by 2035: USD 2.59 Billion
• CAGR (2025–2035): 5.6%
• Leading Market in 2024: North America
• Fastest-Growing Market: Asia-Pacific
• By End-User: The Pharmaceutical and Biotechnology segment is anticipated to lead the market by accounting for 38.76% of the market share throughout the forecast period.
• By Mouse Type: The Genetically Modified Mice segment is expected to capture 30.08% of the market share, thereby maintaining its dominance over the forecast period.
• By Region: North America region is projected to hold 30.33% of the market share during the forecast period.
• Active Players: Biocytogen Co., Ltd. (China), Champions Oncology, Inc. (USA), Charles River Laboratories International, Inc. (USA), Crown Bioscience, Inc. (USA), Cyagen Biosciences Inc. (China), and Other Active Players.

Mice Model Market Synopsis:

The mice model market refers to the global ecosystem supporting the development and use of laboratory mice for preclinical research, disease modeling, and therapeutic evaluation. These models, including inbred, outbred, and genetically engineered mice, are essential for studying human disease mechanisms and drug responses due to their genetic similarity to humans and rapid breeding cycles. Market growth is driven by rising pharmaceutical and biotechnology R&D, increasing prevalence of chronic and rare diseases, and stringent regulatory requirements for preclinical validation. Advances in genetic engineering technologies, particularly CRISPR-Cas9, and growing demand for precision medicine continue to strengthen market adoption across research institutions and commercial laboratories.

Mice Model Market Dynamics and Trend Analysis:

Mice Model Market Growth Driver-Rising Cancer Research and Immuno-Oncology Advancements Accelerating Demand for Mice Models

• The global mice model market is expected to witness strong growth during the forecast period, primarily driven by the rising focus on cancer research worldwide. Cancer remains one of the leading causes of mortality, creating urgent demand for effective and affordable therapies. Mouse models play a critical role in understanding tumor biology, immune responses, and therapeutic efficacy, particularly where in-silico methods are inadequate.
• Growing investment in oncology and immuno-oncology research has accelerated the adoption of advanced and humanized mice models, which offer improved predictive accuracy for clinical outcomes. Innovations such as cord-blood–based and immune-engrafted mouse models are reducing experimental limitations and enhancing translational relevance. Consequently, increasing oncology research funding continues to strengthen demand for specialized mice models across global research markets.

Mice Model Market Limiting Factor-High Development, Maintenance, and Translational Limitations Restraining Market Growth

• The mice model market is restrained by high development and maintenance costs associated with genetic engineering, specialized breeding, skilled personnel, and biosecure housing facilities. Maintaining genetically modified and specific pathogen-free mouse strains requires significant capital investment, limiting accessibility for smaller research institutions and budget-constrained laboratories.
•  Additionally, the technical complexity and time-intensive nature of advanced genetic manipulation increase production timelines and costs. Scientific limitations further challenge market growth, as physiological and genetic differences between mice and humans can reduce translational accuracy, leading to high failure rates in clinical trials. Collectively, these factors constrain scalability, adoption, and overall market penetration despite strong research demand.

Mice Model Market Expansion Opportunity-Expanding R&D Investments and Gene-Editing Innovations Creating Growth Opportunities in the Rat and Mouse Model Market

• The rising intensity of research and development activities across pharmaceutical, biotechnology, and academic sectors is creating significant growth opportunities for the rat and mouse model market. Increased funding is driving the development of genetically precise and disease-specific models that enhance drug metabolism, pharmacokinetics, and translational research outcomes. Advances in gene-editing technologies, particularly CRISPR/Cas9, have shortened model development timelines while improving accuracy and cost efficiency.
• Collaborative efforts between research institutions and industry players are accelerating the introduction of next-generation models for complex and rare diseases. Additionally, integration of advanced phenotyping and imaging technologies further strengthens the research value of these models, positioning them as critical enablers of preclinical innovation and personalized medicine.

Mice Model Market Challenge and Risk-Ethical, Regulatory, and Scientific Limitations Posing Market Challenges

• The rat and mouse model market faces significant challenges arising from increasing ethical scrutiny, stringent regulatory frameworks, and scientific limitations. Growing enforcement of animal welfare regulations and adherence to the 3Rs principles have led to longer approval timelines, higher compliance costs, and restricted experimental flexibility.
• Public concern over animal rights further intensifies oversight, limiting the scale of in vivo research. In parallel, genetic and phenotypic variability between mice and humans can reduce translational reliability, while strain-specific responses affect reproducibility. Additionally, the rising adoption of alternative testing methods such as in vitro systems and computational models presents competitive pressure, collectively constraining market expansion and research efficiency.

Mice Model Market Trend-Growing Adoption of Personalized Medicine, Drug Discovery Expansion, and Gene-Editing Advancements Shaping Market Trends

• The mice model market is witnessing strong momentum driven by the rising adoption of personalized and precision medicine. Genetically engineered, humanized, and patient-derived xenograft (PDX) mouse models are increasingly used to study disease mechanisms, validate biomarkers, and assess individualized drug responses. Simultaneously, expanding drug discovery activities are intensifying reliance on mice models for preclinical evaluation of pharmacokinetics, pharmacodynamics, and therapeutic safety.
• Advances in gene-editing technologies such as CRISPR-based knock-in, knock-out, and conditional expression models have significantly improved development speed, accuracy, and efficiency. These innovations support emerging applications in gene and cell therapy, enabling faster translation of targeted treatments and reinforcing the strategic importance of mice models in modern biomedical research.

Mice Model Market Segment Analysis:

Mice Model Market is segmented based on Mouse Type, Technology, Application, End-User and Region

By End-User, pharmaceutical and biotechnology segment is expected to dominate the market with around 38.76% share during the forecast period.

• By end user, pharmaceutical and biotechnology companies dominate the mice model market, accounting for the largest share due to their extensive investment in drug discovery, preclinical testing, and regulatory submissions. These companies rely heavily on mice models to evaluate safety, efficacy, and disease mechanisms, particularly in oncology, immunology, and rare disease pipelines.
• Their strong financial capacity, large-scale R&D programs, and long-term partnerships with model suppliers ensure consistent access to advanced and customized mouse models, reinforcing segment dominance. Meanwhile, academic and research institutes represent the fastest-growing segment, supported by rising government funding and collaborative research initiatives, while CROs and CDMOs are gaining traction due to increased outsourcing of preclinical research activities.

By Mouse Type, Genetically Modified mice is expected to dominate with close to 30.08% market share during the forecast period.

• Genetically modified mice dominate the market with a 30.08% share in 2024, driven by their critical role in advanced disease modelling and targeted drug discovery. Knockout, knock-in, transgenic, and humanized models allow precise gene manipulation, replicating complex human disease pathways. Their versatility across oncology, immunology, and neuroscience research, combined with genome-editing technologies like CRISPR, accelerates development timelines and customization. High demand from pharmaceutical and biotech companies for preclinical drug efficacy, toxicity, and biomarker studies reinforces their market leadership. These models remain indispensable for precision medicine and translational research.

Mice Model Market Regional Insights:

North America region is estimated to lead the market with around 30.33% share during the forecast period.

• North America is expected to generate the highest revenue in the global mice model market during the forecast period, driven by its strong biomedical research ecosystem and high healthcare expenditure. The region benefits from a high prevalence of chronic and life-threatening diseases such as cancer, cardiovascular disorders, diabetes, neurological conditions, and viral infections, which fuels sustained demand for advanced preclinical models.
• The United States dominates the regional market due to robust pharmaceutical and biotechnology R&D investment, extensive federal research funding, and the presence of leading institutions and suppliers. Continuous advancements in genetic engineering, widespread adoption of humanized and transgenic mice, and well-established regulatory and research infrastructure collectively position North America as the dominant market for mice models globally.

Mice Model Market Active Players:

• Biocytogen Co., Ltd. (China)
• Champions Oncology, Inc. (USA)
• Charles River Laboratories International, Inc. (USA)
• Crown Bioscience, Inc. (USA)
• Cyagen Biosciences Inc. (China)
• Envigo (UK)
• GenOway S.A. (France)
• Horizon Discovery Group plc (UK)
• Janvier Labs (France)
• Laboratory Corporation of America Holdings (Labcorp) (USA)
• Pharmaron, Inc. (China)
• Shanghai Model Organisms Center, Inc. (SMOC) (China)
• Taconic Biosciences, Inc. (USA)
• The Jackson Laboratory (USA)
• Transgenic Inc. (Japan)
• Other Active Players

Key Industry Developments in the Mice Model Market:

• In August 2025, Charles River Laboratories entered a strategic partnership with a biotechnology company to co-develop advanced mouse models for immuno-oncology research, strengthening its portfolio and reinforcing its leadership in specialized oncology-focused preclinical solutions.
• In July 2025, The Jackson Laboratory launched an initiative to expand its genetic mouse model portfolio for rare genetic disorders, supporting personalized medicine research and enhancing its competitive position among niche, disease-focused research institutions.

 Advanced Genetic Engineering Technologies and Preclinical Workflow Architecture in the Mice Model Market

• The technical foundation of the Mice Model Market is centered on advanced genetic manipulation, controlled breeding systems, and standardized preclinical workflows. Mouse models are developed using precise genome-editing technologies such as CRISPR-Cas9, TALENs, and recombinase-based conditional systems to generate knockout, knock-in, transgenic, and humanized strains. Technical processes include strain design, microinjection or electroporation, embryo transfer, genotyping, phenotypic validation, and long-term colony management.
• High-throughput phenotyping, molecular imaging, and multi-omics platforms are increasingly integrated to enhance data accuracy. Cryopreservation and biobanking ensure genetic integrity and scalability. Strict adherence to regulatory guidelines, biosecurity measures, and ethical animal research protocols governs model development, supporting reproducibility, data reliability, and translational relevance across biomedical research applications.